NCT05169801View on ClinicalTrials.gov

To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC

PHASE3CompletedINTERVENTIONAL
Enrollment

520

Participants

Timeline

Start Date

January 25, 2018

Primary Completion Date

October 21, 2019

Study Completion Date

June 17, 2021

Conditions
Non-small Cell Lung Cancer(NSCLC)
Interventions
DRUG

BP102, paclitaxel, carboplatin

BP102, paclitaxel, carboplatin

DRUG

Avastin®, paclitaxel, carboplatin

Avastin®, paclitaxel, carboplatin

Trial Locations (1)

210000

Jiangsu Cancer Hospital, Nanjing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT05169801 - To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC | Biotech Hunter | Biotech Hunter